PHILADELPHIA, Nov. 2, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended September 30, 2012. The net comprehensive loss for the period (including non-cash effects of the redeemable warrants valuation adjustment) was approximately $6,425,000 or $(0.04) per share as compared to a net comprehensive loss of approximately $3,269,000 or ($0.02) per share for the same period in 2011.
